Is the Nanosonics Ltd (ASX: NAN) share price a buy?
Nanosonics manufactures and distributes its breakthrough disinfection product used for ultrasound probe reprocessing. The share price is up a whopping 65% this year and I believe it can go a whole lot higher. Here is why I believe Nanosonics can outperform the S&P/ASX 200.
Let’s start with the market opportunity at hand. Nanosonics is still in its early days of growth and development given the significant global opportunity in the ultrasound probe reprocessing market. The abstract (below) from the company’s HY19 presentation highlights only 16% market penetration despite strong year-on-year installations.
The company’s flagship product, the Trophon has already become a staple standard of care in Australia with approximately 70% market penetration. However, in regions such as Europe, the Middle East and Asia, there remains a significant opportunity.
In 2019, a preliminary clinical study found that over 90% of probes in Japan were contaminated. Of the contaminated probes, over 50% were found to harbour potentially pathogenic bacteria. This is a key opportunity for Nanosonics as they highlight “our business development activities in Japan progressed positively with completion of the first clinical study and establishment of Nanosonics Japan”. With regulatory approval in place in Japan and pre-marketing strategy underway, Nanosonics could be set for some explosive growth in the coming years.
Nanosonics also has a diverse business model that involves capital equipment sales, equipment maintenance and rental services. Given the company’s strong position in the market, the concept of equipment replacements and upgrades presents a significant, almost annuity style of revenue.
I am confident that Nanosonics’ geographical expansion, strategic partnerships and distribution channels will continue to pay dividends to its bottom line.
Is the stock too expensive?
Strong historic growth, a diverse revenue model and many significant global opportunities – it seems too good to be true. Surely there is a twist?
Well, Nanosonics trades at a P/E ratio of around 110. This could be comparable to the way NextDC Ltd (ASX: NXT) is priced, with a P/E ratio of 330. Both companies are incredibly reliable in earnings growth and possess a market leading product that will be highly sought after for many years to come. The market has therefore priced in much of the anticipated upside.
Nanosonics continues to deliver on growth with its half-yearly and annual reports. Clearly, the company still has a long way to go in its global expansion and ongoing R&D. The company anticipates a second clinical study in Japan to be completed by the end of FY19 and regulatory approval of the Trophon 2 expected by the end of FY19. I would strongly consider adding Nanosonics into a portfolio aimed at capital growth.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.